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INTRODUCTION 
Malaria, an infectious disease transmitted by the anopheles 
mosquitoes, contributes to the significant morbidity and 
mortality in the tropics - it is responsible for over three million 
annual deaths
1
. With the increase in intercontinental travelling 
and immigration, there has been a notable rise in the number 
of malaria cases in industrialized countries
2
. The most 
prevalent imported malaria cases are caused by Plasmodium 
falciparum species, which is also responsible for the most 
virulent and lethal malaria infections in humans
1
. Calgary is 
the fourth largest Canadian city to have the highest number of 
immigrants, who consisted 30% of the total city population in 
2010
3
. On average, sixty to hundred malaria cases are reported 
annually in Calgary as determined by the local diagnostic 
laboratory
3
. However, little is known about the epidemiology 
of the patients, such as travel history, type of prophylaxis 
taken and the causative Plasmodium species. Therefore, the 
aim of this retrospective study was to determine whether 
returning travellers to Calgary are vectors of drug-resistant 
strains of malaria and thus a critical sentinel of emerging 
resistance in other parts of the world.  
METHODS 
The study group comprised of patients who were positive for 
P. falciparum malaria between 2007 and 2012 with travel 
history to endemic countries. The following information was 
collected: pre-travel advice, reason for travel, countries with 
malaria visited, types of prophylaxis taken and treatment. The 
data were entered and stored on the Microsoft Access 
database. From this, the following epidemiological data were 
collected: gender, age, geometric mean parasitemia and 
parasite clearance rate. The data were calculated using SPSS, 
Microsoft Excel and Parasite Clearance Estimator tool by 
WWARN. 
 
RESULTS 
Between 2007 and 2012, a total of 209 cases were laboratory-
confirmed in Calgary. The 58.6% of the cases were caused by 
P. falciparum with 119 reported cases where 68.9% were seen 
in males. The mean age of P.falciparum infected males was 
32.5±14.1 and females, 26.5±15.0. The parasite clearance rate 
of eligible patients ranged from 0.0269 to 0.578 (n=31). The 
highest GMP of 0.878 was observed in 2007. A majority of 
travellers received pre-travel advice (61.3%), but 38.7% of 
infected patients had not taken prophylaxis. Almost a half of 
the patients (47.5%) were VFR travellers. Most P. falciparum 
infected patients had travelled to at least one country in Africa. 
  
DISCUSSION AND CONCLUSIONS 
During the 2007 and 2012 period, there was a moderate 
increase in the number of P. falciparum cases, with alternating 
increases and decreases each year. A linear regression 
performed by SPSS showed that there is a non-significant 
(p=0.149) but a moderately increasing trend (r=0.514) in the 
number of P.falciparum cases over the six years. Based on the 
results, the majority of patients infected with P. falciparum 
were, therefore: males aged 30-39, travelled to Africa to VFR, 
did not seek pre-travel advice, did not take prophylaxis and 
had an average parasite clearance rate of 0.116±0.101. One 
limitation of this study is the estimation of parasite clearance 
rate, in which the tool developed by WWARN had very 
specific requirements and reducing the number of eligible 
patients to 31. 
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